Table of contents
- Trial overview
- Hemodialysis and muscle protein turnover
- Nutrition route after oesophagectomy
- Supplementary parenteral nutrition after emergency abdominal surgery
- Main outcomes being measured
- Who the trials are for
- Trial phase and status
Trial overview
The clinical trials listed for Valine are studying nutrition support in patients with serious medical conditions and recovery needs.[1][2][3] All three studies are interventional, which means the researchers are giving a treatment and watching what happens.[1][2][3] Each trial is in Phase 3 and is currently authorised.[1][2][3]
Hemodialysis and muscle protein turnover
The LOTUS trial (NCT 2025-522111-42-02) is studying chronic hemodialysis patients and the effect of intradiialytic parenteral nutrition (IDPN), which is nutrition given during dialysis.[1] The study aims to see whether IDPN changes muscle protein synthesis and to describe its hemodynamic effects, meaning its effects on blood flow and circulation.[1]
The main outcome is the difference in myofibrillar fractional synthetic rate, a measure of how fast new muscle protein is made, during one week of IDPN compared with control treatment.[1] The trial plans to enroll 20 participants.[1]
Nutrition route after oesophagectomy
The trial titled “Route of nutrition and muscle wasting after oesophagectomy” (NCT 2023-507649-27-00) is studying patients after oesophagectomy, which is surgery to remove part or all of the esophagus.[2] Researchers want to understand how the route of nutrition affects cachexia, a term for severe muscle and weight loss during illness.[2]
This study uses SmofKabiven emulsion for infusion and is measuring the mean difference in muscle size on CT scan from before the operation to 10 days after oesophagostomy, as listed in the source data.[2] The planned enrollment is 38 patients.[2]
Supplementary parenteral nutrition after emergency abdominal surgery
The trial “Early versus postponed supplementary parenteral nutrition after major emergency abdominal surgery” (NCT 2023-505378-14-00) is comparing two timing strategies for extra nutrition given through a vein after surgery.[3] The study includes patients recovering from major emergency abdominal surgery.[3]
The intervention uses SmofKabiven Perifer and SmofKabiven, both given by infusion.[3] The main outcome is whether early or delayed supplementary parenteral nutrition reduces infectious complications during the hospital stay.[3] The trial plans to enroll 342 participants.[3]
Main outcomes being measured
The trials focus on practical outcomes that matter in hospital care, such as muscle building, muscle loss, and infection risk.[1][2][3] In the hemodialysis study, the key outcome is muscle protein synthesis measured over one week.[1] In the oesophagectomy study, the key outcome is muscle size on CT scan over time.[2] In the abdominal surgery study, the key outcome is the rate of infections during admission.[3]
Who the trials are for
These studies are not for one single disease group.[1][2][3] One trial is for chronic hemodialysis patients, one is for patients after oesophagectomy, and one is for patients after major emergency abdominal surgery.[1][2][3] The source data does not give full eligibility rules, so the exact entry criteria are not listed here.[1][2][3]
Trial phase and status
All listed Valine trials are in Phase 3, which is a later stage of clinical testing.[1][2][3] The status of each study is Authorised, meaning the trial has been approved to proceed in the source registry data.[1][2][3]




